Incorporation of Prognostic and Predictive Factors Into Glioma Clinical Trials

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802

(2012) Edward G. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors

(2012) Shingo Takano et al.   JOURNAL OF NEURO-ONCOLOGY

Drug Approvals 2011: Focus on Companion Diagnostics

(2012) M. Goozner   JNCI-Journal of the National Cancer Institute

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group

(2012) Evanthia Galanis et al.   LANCET ONCOLOGY

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults

(2011) Adriana Olar et al.   Annals of Diagnostic Pathology

Mutated IDH1 Is a Favorable Prognostic Factor for Type 2 Gliomatosis Cerebri

(2011) Mi Jung Kwon et al.   BRAIN PATHOLOGY

American Society of Clinical Oncology 2011 CNS tumors update

(2011) Manmeet S Ahluwalia   Expert Review of Anticancer Therapy

Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression

(2011) Virginie Desestret et al.   JOURNAL OF NEURO-ONCOLOGY

A multigene predictor of outcome in glioblastoma

(2011) H. Colman et al.   NEURO-ONCOLOGY

Evaluating markers for treatment selection based on survival time

(2011) Xiao Song et al.   STATISTICS IN MEDICINE

Analysis of randomized comparative clinical trial data for personalized treatment selections

(2010) T. Cai et al.   BIOSTATISTICS

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2010) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Designing a Randomized Clinical Trial to Evaluate Personalized Medicine: A New Approach Based on Risk Prediction

(2010) S. G. Baker et al.   JNCI-Journal of the National Cancer Institute

Randomized Clinical Trials With Biomarkers: Design Issues

(2010) B. Freidlin et al.   JNCI-Journal of the National Cancer Institute

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

The Path to Personalized Medicine

(2010) Margaret A. Hamburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

(2009) AD Barker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges

(2009) Sumithra J. Mandrekar et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

(2009) M. J. Clarke et al.   MOLECULAR CANCER THERAPEUTICS

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

(2009) J. H. Sampson et al.   MOLECULAR CANCER THERAPEUTICS

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE